Global Eye Trials
Global Eye Trials is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA).
Sponsor Splicebio S.L.
- Start (EU)
- Latest update
- Estimated end
ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Global Eye Trials?
The 2026-10-09 snapshot links Global Eye Trials to 4 distinct CTIS trials. Recorded services include BCVA Lane Certification, Certification of Visual Acuity Examiners, Medical expertise, Visual Acuity and Refraction certification. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Global Eye Trials?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Ophthalmology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Global Eye Trials conducted?
The linked trials record locations in 13 countries, including Germany, Spain, France, Belgium, Czechia. These are trial locations, not confirmed office locations or countries where Global Eye Trials delivered services.
What can this page tell me about Global Eye Trials's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Global Eye Trials. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Global Eye Trials Limited
- Global Eye Trials Ltd.